Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Tg 873870
2. Tg-873870
3. Tg873870
1. 378746-64-6
2. Nemonoxacin [inn]
3. Tg-873870
4. Taigexyn
5. P94l0pvo94
6. 7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxoquinoline-3-carboxylic Acid
7. Tg873870
8. 7-((3s,5s)-3-amino-5-methylpiperidin-1-yl)-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
9. Unii-p94l0pvo94
10. 7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
11. Starbld0028467
12. Tg 873870
13. Nemonoxacin [who-dd]
14. Schembl1006373
15. Chembl1213456
16. Gtpl10836
17. Dtxsid10958907
18. Tqp0855
19. Chebi:136053
20. Zinc40435195
21. Db06600
22. Hy-14956
23. Cs-0003656
24. Q15425793
25. 3-quinolinecarboxylic Acid, 7-((3s,5s)-3-amino-5-methyl-1-piperidinyl)-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-
26. 7-[(3s,5s)-3-amino-5-methylpiperidin-1-yl]-1-cyclopropyl-8-methoxy-4- Oxo-1,4-dihydroquinoline-3-carboxylic Acid
| Molecular Weight | 371.4 g/mol |
|---|---|
| Molecular Formula | C20H25N3O4 |
| XLogP3 | 0.4 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 371.18450629 g/mol |
| Monoisotopic Mass | 371.18450629 g/mol |
| Topological Polar Surface Area | 96.1 Ų |
| Heavy Atom Count | 27 |
| Formal Charge | 0 |
| Complexity | 647 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in bacterial infection and pneumonia.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01M - Quinolone antibacterials
J01MB - Other quinolones
J01MB08 - Nemonoxacin
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Nemonoxacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nemonoxacin, including repackagers and relabelers. The FDA regulates Nemonoxacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nemonoxacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Nemonoxacin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Nemonoxacin supplier is an individual or a company that provides Nemonoxacin active pharmaceutical ingredient (API) or Nemonoxacin finished formulations upon request. The Nemonoxacin suppliers may include Nemonoxacin API manufacturers, exporters, distributors and traders.
click here to find a list of Nemonoxacin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Nemonoxacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nemonoxacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nemonoxacin GMP manufacturer or Nemonoxacin GMP API supplier for your needs.
A Nemonoxacin CoA (Certificate of Analysis) is a formal document that attests to Nemonoxacin's compliance with Nemonoxacin specifications and serves as a tool for batch-level quality control.
Nemonoxacin CoA mostly includes findings from lab analyses of a specific batch. For each Nemonoxacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nemonoxacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Nemonoxacin EP), Nemonoxacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nemonoxacin USP).
LOOKING FOR A SUPPLIER?
